# reload+after+2024-01-20 00:43:24.023661
address1§2401 4th Avenue
address2§Suite 1050
city§Seattle
state§WA
zip§98121
country§United States
phone§206 838 0500
fax§206 838 0503
website§https://www.aptevotherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
fullTimeEmployees§45
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Marvin L. White', 'age': 61, 'title': 'President, CEO & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 892861, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeffrey G. Lamothe CA', 'age': 57, 'title': 'Executive VP & COO', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 691369, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. SoYoung  Kwon J.D., LL.M.', 'title': 'Senior VP, General Counsel, Business Development & Corporate Affairs', 'fiscalYear': 2022, 'totalPay': 588033, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Daphne L. Taylor', 'age': 57, 'title': 'Senior VP & CFO', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jane A. Gross Ph.D.', 'age': 66, 'title': 'Chief Scientific Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 515169, 'exercisedValue': 0, 'unexercisedValue': 2888}, {'maxAge': 1, 'name': 'Dr. Dirk  Huebner M.D.', 'age': 60, 'title': 'Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§4.906
priceToSalesTrailing12Months§Infinity
currency§USD
dateShortInterest§1702598400
forwardEps§-1.33
exchange§NCM
quoteType§EQUITY
shortName§Aptevo Therapeutics Inc.
longName§Aptevo Therapeutics Inc.
firstTradeDateEpochUtc§1469021400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§470316e1-b879-3a10-830d-ae029cd54a71
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§4.75
targetMeanPrice§7.38
targetMedianPrice§7.38
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§2.795
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
